Diabetic Nephropathies
Medicine & Life Sciences
100%
Kidney
Medicine & Life Sciences
67%
Type 1 Diabetes Mellitus
Medicine & Life Sciences
49%
Type 2 Diabetes Mellitus
Medicine & Life Sciences
45%
AMP-Activated Protein Kinases
Medicine & Life Sciences
40%
Albuminuria
Medicine & Life Sciences
39%
monohydrochloride 1-((2-adamantyl)amino)acetyl-2-cyano-(S)-pyrrolidine
Medicine & Life Sciences
29%
Anti-Inflammatory Agents
Medicine & Life Sciences
28%
Canagliflozin
100%
Glomerular Filtration Rate
59%
Type 2 Diabetes Mellitus
47%
Sodium-Glucose Transporter 2 Inhibitors
45%
Symporters
43%
Oda, K. ,
Miyamoto, S. ,
Kodera, R. ,
Wada, J. &
Shikata, K. ,
2022 , (Accepted/In press)
In: Journal of Diabetes Investigation. 研究成果 › 査読
Suramin
100%
Inflammasomes
88%
Diabetic Nephropathies
78%
Mesangial Cells
44%
Interleukin-18
32%
the Diabetic Nephropathy Remission and Regression Team Trial in Japan (DNETT-Japan) collaborative group ,
2月 2021 ,
In: Journal of Diabetes Investigation. 12 ,
2 ,
p. 207-216 10 p. 研究成果 › 査読
Diabetic Nephropathies
100%
Japan
77%
Creatinine
33%
Hydroxymethylglutaryl-CoA Reductase Inhibitors
20%
Confidence Intervals
18%
Nojima, I. ,
Eikawa, S. ,
Tomonobu, N. ,
Hada, Y. ,
Kajitani, N. ,
Teshigawara, S. ,
Miyamoto, S. ,
Tone, A. ,
Uchida, H. A. ,
Nakatsuka, A. ,
Eguchi, J. ,
Shikata, K. ,
Udono, H. &
Wada, J. ,
12月 1 2020 ,
In: Scientific reports. 10 ,
1 , 14928.
研究成果 › 査読
Metformin
100%
Type 2 Diabetes Mellitus
69%
Glycolysis
58%
T-Lymphocytes
57%
Sucrose
36%
Diabetic Nephropathies
100%
Hypoglycemia
26%
Drug Development
25%
methyl 2-cyano-3,12-dioxoolean-1,9-dien-28-oate
24%
Chronic Kidney Failure
23%